Nabros Pharma Profile
Key Indicators
- Authorised Capital ₹ 1.00 Cr
as on 08-12-2024
- Paid Up Capital ₹ 4.70 M
as on 08-12-2024
- Company Age 41 Year, 22 Days
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 4.50 M
as on 08-12-2024
- Revenue 6.82%
(FY 2022)
- Profit 10.61%
(FY 2022)
- Ebitda 18.60%
(FY 2022)
- Net Worth 9.52%
(FY 2022)
- Total Assets 9.71%
(FY 2022)
About Nabros Pharma
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 1.00 Cr and a paid-up capital of Rs 4.70 M.
The company currently has active open charges totaling ₹4.50 M.
Amit Shah, Narendrakumar Darbar, Kavit Shah, and Two other members serve as directors at the Company.
- CIN/LLPIN
U24230GJ1983PTC006628
- Company No.
006628
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
29 Dec 1983
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Ahmedabad
Industry
Company Details
- Location
Ahmedabad, Gujarat, India
- Telephone
- Email Address
- Website
- Social Media-
What products or services does Nabros Pharma Private Limited offer?
Nabros Pharma Private Limited offers a wide range of products and services, including Sexual Wellness Products, Female Hygiene Products & Test Kits, Mosquito Repellent, Mosquito Repellent Cream, Toothpastes, Sensitivity Toothpaste.
Who are the key members and board of directors at Nabros Pharma?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Narendrakumar Darbar  | Managing Director | 11-Apr-2024 | Current |
Board Members(4)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Amit Shah | Director | 11-Apr-2024 | Current |
| Kavit Shah | Whole-Time Director | 05-Apr-2009 | Current |
| Rupeshkumar Shah | Director | 01-Jan-2016 | Current |
| Chandrikaben Shah | Whole-Time Director | 29-Oct-1984 | Current |
Financial Performance of Nabros Pharma.
Nabros Pharma Private Limited, for the financial year ended 2022, experienced modest growth in revenue, with a 6.82% increase. The company also saw a substantial improvement in profitability, with a 10.61% increase in profit. The company's net worth moved up by a moderate rise of 9.52%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Nabros Pharma?
In 2023, Nabros Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Charges (Loans)
| Lender | Amount | Status |
|---|---|---|
Canara Bank Creation Date: 30 Dec 1997 | ₹4.50 M | Open |
How Many Employees Work at Nabros Pharma?
Nabros Pharma has a workforce of 48 employees as of Mar 22, 2024. Unlock access to detailed historical data on individuals associated with the company, including employment records, contributions to the Employees' Provident Fund Organization (EPFO), and other related insights.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Nabros Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Nabros Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
